Corticosteroid-Sparing Effect of Intravenous Immunoglobulin Therapy in Patients With Pemphigus Vulgaris

Minimizing Complications in Autoimmune Blistering Diseases

“…Association of IVIG with acute renal failure mandates careful evaluation of the benefit/ risk ratio in patients with a history of renal disease. [20][21][22] Rituximab is a monoclonal antibody against the CD20 antigen on mature B cells. Treatment with this agent is often effective in AIBD.…”

Rituximab treatment of severe pemphigus: Long-term results including immunologic follow-up

“…8 Adjuvant intravenous immunoglobulins (IVIg) have been proposed as a therapeutic alternative, and achieved clinical disease control and corticosteroidsparing, but not prolonged complete remission (CR) without treatment. 9,10 Rituximab (RTX), a monoclonal antibody directed against the CD20 antigen expressed on B lymphocytes, was recently shown to be effective against severe pemphigus, using either multiple cycles combined with IVIg 11 or a single cycle. 12 However, its long-term efficacy, particularly the possibility of prolonged CR with or without maintenance therapy, remains to be proven.…”

A randomized double-blind trial of intravenous immunoglobulin for pemphigus

“…2 No well-controlled, double-blind clinical study to demonstrate the efficacy of HD-IVIG has been conducted. [3][4][5][6][7][8][9][10][11][12][13] This is because: (1) pemphigus is a rare intractable disease;…”